Ataia, Inc.

Ataia, Inc. is a medical device company that focuses on enhancing communication solutions for patients using non-invasive ventilation therapies, particularly through their innovative product, SPEAX. Founded in 2017 in Dallas, US, Ataia, Inc. specializes in communication solutions for patients undergoing non-invasive ventilation.

The company has completed one deal and received Seed funding of USD 0. 3 mn led by Green Park & Golf Ventures in July 2018. The CEO of Ataia is Tyler Register, and the founders include A. Wong, Amber Jackson, Amy Foertsch, and Tyler Register.

Ataia Medical specializes in innovative communication solutions for patients undergoing non-invasive ventilation therapies, specifically through their flagship product, SPEAX. This two-piece device facilitates verbal communication for individuals using CPAP (Continuous Positive Airway Pressure) and BiPAP (Bilevel Positive Airway Pressure) machines, commonly employed for patients with conditions such as ALS (Amyotrophic Lateral Sclerosis), muscular dystrophy (MD), and chronic obstructive pulmonary disease (COPD). SPEAX addresses communication barriers posed by traditional ventilation masks, enabling users to converse with caregivers and loved ones, thereby enhancing their participation in daily life and medical decision-making. The product is marketed primarily in North America, targeting patients, family members, and healthcare professionals involved in the care of individuals requiring long-term ventilation support.

Ataia Medical generates revenue through direct sales of the SPEAX communication device to patients and healthcare providers, as well as potential partnerships with hospitals and rehabilitation centers. The transaction structure is primarily B2B, focusing on distributing the product to clinical settings for patient use. Sales are structured as one-time purchases, allowing healthcare facilities to procure SPEAX for patient use. Pricing details for the SPEAX product line are not disclosed, however, healthcare providers and patients engage with the company through direct orders, aiming to improve patient communication and overall quality of care during their treatment journey.

Ataia plans to leverage the recent Seed funding of USD 0. 3 mn received in July 2018 to support its growth initiatives. The company is working on introducing new products to enhance patient communication in respiratory care, with specific details on release dates yet to be announced. Additionally, Ataia aims to expand its market presence beyond North America, targeting new geographic regions to increase accessibility for patients in need of non-invasive ventilation solutions.

This expansion is part of their strategy to improve patient outcomes and engagement in their treatment journey.